Literature DB >> 3508569

Kinetics of potassium excretion following oral supplements: evidence of induced natriuresis.

A Rakhit1, S Melethil, J D Arnold, W E Wagner.   

Abstract

Twenty-four healthy normal volunteers were given 40 mEq of three oral formulations of K+ as potassium chloride in a three-way Latin square design. Pharmacokinetic characteristics of potassium disposition were determined using urinary excretion data. Potassium was absorbed almost instantaneously from the 10% (w/v) solution, while a slow first-order absorption could explain the slow release of potassium from Slow-K and the new slow-release tablet. A biphasic elimination of potassium observed during the first 24 hr of urinary excretion suggested the body's adaptive process of changes in rates of elimination of potassium to maintain homeostasis. There was no significant difference (P = 0.25) in total recoveries of potassium in urine during 48 hr of urinary collection among the three formulations (mean +/- SE: solution, 35 +/- 7.1 mEq; Slow-K, 38.1 +/- 7.8 mEq; and new formulations, 33.5 +/- 6.8 mEq). An increased excretion of sodium was observed and correlated with increased potassium excretion following oral potassium administration which could not be explained by changes in urine flow rate. The clinical significance of such an increase in natriuresis is yet to be determined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508569     DOI: 10.1023/a:1016496026017

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  SMALL-BOWEL ULCERATION APPARENTLY ASSOCIATED WITH THIAZIDE AND POTASSIUM THERAPY.

Authors:  D R BAKER; W H SCHRADER; C R HITCHCOCK
Journal:  JAMA       Date:  1964-11-16       Impact factor: 56.272

2.  THE CIRCUMFERENTIAL SMALL-BOWEL ULCER: CLINICAL ASPECTS IN 17 PATIENTS.

Authors:  L MORGENSTERN; M FREILICH; J F PANISH
Journal:  JAMA       Date:  1965-02-22       Impact factor: 56.272

3.  EXPERIMENTAL EVALUATION OF THIAZIDES AND POTASSIUM AS A CAUSE OF SMALL-BOWEL ULCER.

Authors:  S J BOLEY; L SCHULTZ; H KRIEGER; S SCHWARTZ; A ELGUEZABAL; A C ALLEN
Journal:  JAMA       Date:  1965-05-31       Impact factor: 56.272

4.  POTASSIUM-INDUCED LESIONS OF THE SMALL BOWEL. I. CLINICAL ASPECTS.

Authors:  S J BOLEY; A C ALLEN; L SCHULTZ; S SCHWARTZ
Journal:  JAMA       Date:  1965-09-20       Impact factor: 56.272

5.  Absence of gastrointestinal bleeding with controlled-release potassium chloride tablets.

Authors:  M B Maggio-Cavaliere; W G Dukstein; J D Arnold; A E Berger
Journal:  Clin Pharmacol Ther       Date:  1974-10       Impact factor: 6.875

6.  Bioavailability of potassium from a slow-release tablet.

Authors:  D Ben-Ishay; K Engelman
Journal:  Clin Pharmacol Ther       Date:  1973 Mar-Apr       Impact factor: 6.875

7.  Bioavailability and pharmacokinetics of a new, slow-release potassium chloride capsule.

Authors:  J Arnold; J T Jacob; B Riley
Journal:  J Pharm Sci       Date:  1980-12       Impact factor: 3.534

8.  Potassium chloride and intestinal ulceration.

Authors:  V Wynn
Journal:  Lancet       Date:  1965-12-11       Impact factor: 79.321

9.  Bioavailability of potassium from controlled-release tablets with and without water loading.

Authors:  H Bechgaard; N W Shephard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  9 in total
  2 in total

1.  Formulation, bioavailability, and pharmacokinetics of sustained-release potassium chloride tablets.

Authors:  S Senel; Y Capan; T Dalkara; N Inanç; A A Hincal
Journal:  Pharm Res       Date:  1991-10       Impact factor: 4.200

2.  Development and bioequivalence study of potassium chloride extended release tablets.

Authors:  Thu Van Le Thi; Nghiem Le Quan; Hau Le
Journal:  Asian J Pharm Sci       Date:  2017-10-23       Impact factor: 6.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.